10x Genomics (MEX:TXG) Cash-to-Debt : 4.64 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 10x Genomics's cash to debt ratio for the quarter that ended in Sep. 2024 was 4.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 10x Genomics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for 10x Genomics's Cash-to-Debt or its related term are showing as below:

MEX:TXG' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.89 Med: 4.87 Max: 14.4
Current: 4.64

During the past 7 years, 10x Genomics's highest Cash to Debt Ratio was 14.40. The lowest was 1.89. And the median was 4.87.

MEX:TXG's Cash-to-Debt is ranked better than
74.92% of 666 companies
in the Healthcare Providers & Services industry
Industry Median: 0.765 vs MEX:TXG: 4.64

10x Genomics Cash-to-Debt Historical Data

The historical data trend for 10x Genomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

10x Genomics Cash-to-Debt Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

14.27

10.54

7.17

4.52

4.08

10x Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															3.62	4.08	4.03	4.25	4.64

Competitive Comparison of 10x Genomics's Cash-to-Debt

For the Health Information Services subindustry, 10x Genomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

10x Genomics's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Cash-to-Debt falls into.

10x Genomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

10x Genomics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6597.805	/	(195.56	+	1423.274)
	=	4.08

10x Genomics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7839.87	/	(185.384	+	1505.54)
	=	4.64

10x Genomics (MEX:TXG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

10x Genomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.